التفاصيل البيبلوغرافية
| العنوان: |
Tracking tumor evolution during the first-line treatment in brain glioma via serial profiling of cellfree tumor DNA from tumor in situ fluid. |
| المؤلفون: |
Zhiyuan Sheng, Chaojie Bu, Jie Mei, Sensen Xu, Ziyue Zhang, Guangzhong Guo, Yushuai Gao, Liyuan Xing, Zhongcan Chen, Juha Hernesniemi, Ajmal Zemmar, Xingyao Bu |
| المصدر: |
Frontiers in Oncology; 2023, p1-12, 12p |
| مصطلحات موضوعية: |
CIRCULATING tumor DNA, GLIOMAS, BRAIN tumors, TUMORS |
| مصطلحات جغرافية: |
HENAN Sheng (China) |
| مستخلص: |
Objective: Tumor in situ fluid (TISF) refers to the fluid within surgical cavities of glioma. Several studies preliminarily proved the value of cell-free tumor DNA (cftDNA) from TISF in the dynamic characterization of the glioma genome. Here, we assessed the potential utility of TISF cf-tDNA in broad aspects of tumor evolution under therapeutic pressure. Methods: This study was conducted under an Institutional Review Boardapproved protocol at Henan Provincial People's Hospital (China). Cf-tDNA samples were sequenced with a designed 68-gene panel. A total of 205 cftDNA samples from 107 patients were studied. The clinical relevance of serial cftDNA profiling during the postoperative course was analyzed. Results: At least one tumor mutations were detected in 179/205 (87.3%) TISF cftDNA samples. Serial cf-tDNA was complementary to molecular residual disease and to initial tumors. Serial cf-tDNA revealed the selection of pre-existing mismatch repair-deficient cells by temozolomide as a resistant mechanism. Cf-tDNA parameters during treatment were predictive of recurrence, and serial cf-tDNA monitoring had diagnostic value for early recurrence. A total of 223 potentially actionable genomic alterations were assessed in cf-tDNA samples, wherein 78% were not found in any tumor tissue. Conclusions: In conclusion, serial TISF cf-tDNA profiling is valuable in tracking the tumor evolution of glioma during treatment and may be a feasible non-invasive option for monitoring glioma in future prospective studies and clinical practice. [ABSTRACT FROM AUTHOR] |
|
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder